Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796055 · ClinicalTrials.gov registry record · Phase 1
Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00796055 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 6 participants.
The verdict
NCT00796055, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors.
Interventions
- DRUG MEDI-547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796055
The ClinicalTrials.gov registry entry for NCT00796055 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-547 is the first listed.
NCT00796055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796055 about?
NCT00796055 is a clinical study titled "Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors". To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors.
What is the current status of trial NCT00796055?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2009-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00796055?
The interventions under investigation include: MEDI-547 (DRUG).
Who is sponsoring clinical trial NCT00796055?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.